Airway Involvement in Relapsing Polychondritis: Choosing a Biologic on Thin Evidence
A single patient whose relapsing polychondritis has reached her airway. The disagreement is between the biologic with more evidence behind it and the one that's faster to reverse if something goes wrong.
Celia B. built a career as a voice teacher after her own years performing opera professionally, and has spent three years managing relapsing polychondritis — recurrent auricular chondritis and a nasal saddle deformity from an earlier cartilage collapse — on prednisone tapers and methotrexate for flares, well enough that it rarely interrupted her teaching. That changed over the past two months: new hoarseness, devastating for someone whose entire profession runs through her voice, along with inspiratory stridor on exertion. A CT of the neck shows tracheal wall thickening with early luminal narrowing — not a fixed critical stenosis yet, but a real, active process in the one location relapsing polychondritis can turn from disfiguring into life-threatening.
The evidence guiding what comes next is genuinely thin — no randomized trial of any biologic exists in this disease, a rare enough condition that the literature is built almost entirely from small retrospective cohorts and case series. The largest study that exists is Moulis and colleagues' French national series of 41 patients across 105 separate biologic exposures, and its numbers are worth reading carefully before anyone claims a favorite. Tumor necrosis factor inhibitors were by far the most-used agents, at 60 exposures, against 17 for tocilizumab and 15 for anakinra; the overall response rate in the first six months was 62.9%, complete response only 19.0%, and the study identified no trend that would tell a clinician which agent to reach for. So the gap the team is about to argue over — tocilizumab's seventeen exposures against anakinra's fifteen — is not a hierarchy at all. What distinguishes them is not efficacy data but pharmacokinetics: anakinra's half-life of a few hours against tocilizumab's multi-week interval dosing, a property that matters more than usual when the organ actually at risk is an airway that may not tolerate a slow way to reverse course if something goes wrong.
In clinic, new stridor and a thin evidence base
No controlled trial exists for any biologic in relapsing polychondritis — I want to be upfront about how thin this evidence base is. What we do have is Moulis's French series — 41 patients, 105 biologic exposures, 62.9% responding at six months and 19% completely — plus scattered reports of tocilizumab benefiting airway-involved patients specifically. I'd start tocilizumab, and I'd rather defend that as a considered preference inside a thin literature than dress it up as an evidence-based choice.
I'm not going to argue the drug choice directly. But whichever biologic you start will take weeks to show any effect, and her CT already shows early luminal narrowing with symptomatic stridor on exertion. The airway itself needs its own plan — serial laryngoscopy, a low threshold for ENT or pulmonology re-evaluation, and an explicit trigger for what escalation looks like.
No drug decision made today protects her from an acute event next week. That plan has to exist regardless of which biologic wins this conversation.
I'd put the arithmetic on the table, because I think it decides more than either of us has admitted: in Moulis's series tocilizumab has seventeen exposures and anakinra fifteen. Two. That is not an evidence gap, it is a rounding difference, and the same study found no trend favoring any agent over another.
But anakinra has a half-life of a few hours against tocilizumab's multi-week interval dosing, and that's a genuine, patient-specific safety property given the organ actually at risk here. If either drug fails to prevent progression, or seems to be causing harm, being able to stop it and have it clear within a day matters more than usual when the potential downside is airway compromise.
I don't think the evidence gap between the two drugs is large enough to override that asymmetry in a case where the cost of a slow-to-reverse wrong choice is this high.
Agreed on the process, not the drug: serial laryngoscopy, pulmonology co-management, and an explicit trigger point for airway intervention start immediately, regardless of which biologic is chosen.
On the biologic itself, no consensus — the rheumatologist started tocilizumab that day based on its comparatively larger retrospective experience, while the second rheumatologist maintained, without conceding, that anakinra's reversibility was the more important property given the organ actually at risk, and would have chosen differently if the decision were his alone. Both agreed the evidence base is too thin for either position to claim it was clearly right.